Skip to main content

Table 3 Demographic and clinical characteristics in the study population at enrolment (n = 63)

From: Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses

Groups a

0

1

2

3

4

5

6

Total

 

EcoVag®

Lc4R5

Lc23B33

Lc21M49

Lg14869

Lg14869

LaciBios®

 
 

Lg 14869

Lg 20M39

Lg 6M9

Lg 6M9

Lr 14870

Lr 14870

Lr GR-1

 
 

Lr 14870

Lj 22B42

Lj 12B1

Lc 8R6

Lg 15527

Lg 15527

Lr RC-14

 
 

Vaginal

Vaginal

Vaginal

Vaginal

Vaginal

Oral

Oral

 
 

n = 9

n = 12

n = 10

n = 10

n = 9

n = 4

n = 9

n = 63

Mean age (range)

34.2 (19-55)

36.6 (26-48)

35.3 (25-45)

32.7 (25-39)

33.3 (21-46)

33.0 (25-38)

34.7 (21-45)

34.2 (19-55)

Patients with history of BV (no.)

3

6

5

5

3

0

1

23 (36.5%)

Patients with Mobiluncus on microscopy (no.)

4

6

5

3

4

2

2

26 (41.3%)

Length of symptoms of BV (months, mean and range)c

10.7 (1-24)

10.7 (1-48)

14.1 (1-60)

7.9 (1-48)

18.3 (2-60)

3.3 (2-6)

9.5 (1-24)

11.3 (1-60)

Patients with new relation (no.)

8

6 (2 divorced)

8 (1 divorced)

6 (2 divorced)

6

3 (1 divorced)

4

36 (57.1%)

New relation before symptoms appear (no.)

8

6

8

6

6

3

3

35 (55.6%)

Length of symptoms of BV among women with new relation (months, mean and range)

10.5(1-24)

6.5 (1-12)

14.4 (1-60)

4.5 (2-11)

11.3 (2-46)

3.3 (2-6)

11.2 (1-24)

8.2 (1-46)

  1. a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii
  2. b Capsules contain the two strains from EcoVag® plus an additional strain, L. gasseri DSM 15527, belonging to Bifodan A/S
  3. c One patient in group 3, 5, 6 and two patients in group 4 could not give any information since how long time she had symptoms of BV.